Restricted accessResearch articleFirst published online 2014-06
Adeno-Associated Virus-Mediated Overexpression of LARGE Rescues α-Dystroglycan Function in Dystrophic Mice with Mutations in the Fukutin-Related Protein
Multiple genes (e.g., POMT1, POMT2, POMGnT1, ISPD, GTDC2, B3GALNT2, FKTN, FKRP, and LARGE) are known to be involved in the glycosylation pathway of α-dystroglycan (α-DG). Mutations of these genes result in muscular dystrophies with wide phenotypic variability. Abnormal glycosylation of α-DG with decreased extracellular ligand binding activity is a common biochemical feature of these genetic diseases. While it is known that LARGE overexpression can compensate for defects in a few aforementioned genes, it is unclear whether it can also rescue defects in FKRP function. We examined adeno-associated virus (AAV)-mediated LARGE or FKRP overexpression in two dystrophic mouse models with loss-of-function mutations: (1) Largemyd (LARGE gene) and (2) FKRPP448L (FKRP gene). The results agree with previous findings that overexpression of LARGE can ameliorate the dystrophic phenotypes of Largemyd mice. In addition, LARGE overexpression in the FKRPP448L mice effectively generated functional glycosylation (hyperglycosylation) of α-DG and improved dystrophic pathologies in treated muscles. Conversely, FKRP transgene overexpression failed to rescue the defect in glycosylation and improve the phenotypes of the Largemyd mice. Our findings suggest that AAV-mediated LARGE gene therapy may still be a viable therapeutic strategy for dystroglycanopathies with FKRP deficiency.
Get full access to this article
View all access options for this article.
References
1.
AyusoE., MingozziF., MontaneJ., et al. (2010). High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther., 17, 503–510.
2.
BarresiR., MicheleD.E., KanagawaM., et al. (2004). LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med., 10, 696–703.
3.
Beltrán-Valero De BernabéD., CurrierS., SteinbrecherA., et al. (2002). Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am. J. Hum. Genet., 71, 1033–1043.
4.
Beltrán-Valero De BernabéD., VoitT., LongmanC., et al. (2004). Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker–Warburg syndrome. J. Med. Genet., 41, e61.
5.
BlaeserA., KeramarisE., ChanY., et al. (2013). Mouse models of fukutin-related protein mutations show a wide range of disease phenotypes. Hum. Genet., 132, 923–934.
6.
BrockingtonM., TorelliS., PrandiniP., et al. (2005). Localization and functional analysis of the LARGE family of glycosyltransferases: significance for muscular dystrophy. Hum. Mol. Genet., 14, 657–665.
7.
BrockingtonM., TorelliS., SharpP.S., et al. (2010). Transgenic overexpression of LARGE induces α-dystroglycan hyperglycosylation in skeletal and cardiac muscle. PLoS ONE, 5, e14434.
8.
BrownS.C., TorelliS., BrockingtonM., et al. (2004). Abnormalities in α-dystroglycan expression in MDC1C and LGMD2I muscular dystrophies. Am. J. Pathol., 164, 727–737.
9.
CampanelliJ.T., RoberdsS.L., CampbellK.P., and SchellerR.H. (1994). A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. Cell, 77, 663–674.
10.
CampbellK.P. (1995). Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell, 80, 675–679.
11.
ChanY.M., Keramaris-VrantsisE., LidovH.G., et al. (2010). Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum. Mol. Genet., 19, 3995–4006.
12.
CombsA.C., and ErvastiJ.M. (2005). Enhanced laminin binding by α-dystroglycan after enzymatic deglycosylation. Biochem. J., 390, 303–309.
13.
ErvastiJ.M., and CampbellK.P. (1991). Membrane organization of the dystrophin-glycoprotein complex. Cell, 66, 1121–1131.
14.
ErvastiJ., and CampbellK. (1993). A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol., 122, 809–823.
15.
ErvastiJ.M., OhlendieckK., KahlS.D., et al. (1990). Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature, 345, 315–319.
16.
EvanG.I., LewisG.K., RamsayG., and BishopJ.M. (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol. Cell. Biol., 5, 3610–3616.
17.
GeeS.H., MontanaroF., LindenbaumM.H., and CarbonettoS. (1994). Dystroglycan-α, a dystrophin-associated glycoprotein, is a functional agrin receptor. Cell, 77, 675–686.
18.
GrewalP.K., MclaughlanJ.M., MooreC.J., et al. (2005). Characterization of the LARGE family of putative glycosyltransferases associated with dystroglycanopathies. Glycobiology, 15, 912–923.
19.
HuY., LiZ.-F., WuX., and LuQ. (2011). Large induces functional glycans in an O-mannosylation dependent manner and targets GlcNAc terminals on alpha-dystroglycan. PLoS ONE, 6, e16866.
20.
Ibraghimov-BeskrovnayaO., ErvastiJ.M., LeveilleC.J., et al. (1992). Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. Nature, 355, 696–702.
21.
InagakiK., FuessS., StormT.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther., 14, 45–53.
22.
InamoriK.-I., Yoshida-MoriguchiT., HaraY., et al. (2012). Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science, 335, 93–96.
23.
KugaA., KanagawaM., SudoA., et al. (2012). Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan. J. Biol. Chem., 287, 9560–9567.
24.
ManyaH., ChibaA., YoshidaA., et al. (2004). Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc. Natl. Acad. Sci. USA, 101, 500–505.
25.
MercuriE., TopalogluH., BrockingtonM., et al. (2006). Spectrum of brain changes in patients with congenital muscular dystrophy and FKRP gene mutations. Arch. Neurol., 63, 251–257.
26.
OgawaM., NakamuraN., NakayamaY., et al. (2013). GTDC2 modifies O-mannosylated α-dystroglycan in the endoplasmic reticulum to generate N-acetyl glucosamine epitopes reactive with CTD110.6 antibody. Biochem. Biophys. Res. Commun., 440, 88–93.
27.
PacakC.A., MahC.S., ThattaliyathB.D., et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res., 99, e3–e9.
28.
PatnaikS.K., and StanleyP. (2005). Mouse Large can modify complex N- and mucin O-glycans on α-dystroglycan to induce laminin binding. J. Biol. Chem., 280, 20851–20859.
29.
RohrU.-P., HeydF., NeukirchenJ., et al. (2005). Quantitative real-time PCR for titration of infectious recombinant AAV-2 particles. J. Virol. Methods, 127, 40–45.
30.
RoscioliT., KamsteegE.-J., BuysseK., et al. (2012). Mutations in ISPD cause Walker-Warburg syndrome and defective glycosylation of α-dystroglycan. Nat. Genet., 44, 581–585.
31.
StevensE., Carss Kerenj., CirakS., et al. (2013). Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. Am. J. Hum. Genet., 92, 354–365.
32.
TaltsJ.F., AndacZ., GohringW., et al. (1999). Binding of the G domains of laminin α1 and α2 chains and perlecan to heparin, sulfatides, α-dystroglycan and several extracellular matrix proteins. EMBO J., 18, 863–870.
33.
TodaT., KobayashiK., Kondo-IidaE., et al. (2000). The Fukuyama congenital muscular dystrophy story. Neuromuscul. Disord., 10, 153–159.
34.
Van ReeuwijkJ., JanssenM., Van Den ElzenC., et al. (2005). POMT2 mutations cause α-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J. Med. Genet., 42, 907–912.
35.
VeldwijkM.R., TopalyJ., LaufsS., et al. (2002). Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol. Ther., 6, 272–278.
36.
WhitmoreC., Fernandez-FuenteM., BoolerH., et al. (2013). The transgenic expression of LARGE exacerbates the muscle phenotype of dystroglycanopathy mice. Hum. Mol. Genet., 23, 1842–1855.
37.
XiaoX., LiJ., and SamulskiR.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol., 72, 2224–2232.
38.
XuL., LuP.J., WangC.-H., et al. (2013). Adeno-associated virus 9 mediated FKRP gene therapy restores functional glycosylation of α-dystroglycan and improves muscle functions. Mol. Ther., 10, 1832–1840.
39.
YoshidaM., and OzawaE. (1990). Glycoprotein complex anchoring dystrophin to sarcolemma. J. Biochem. (Tokyo), 108, 748–752.
40.
YoshidaA., KobayashiK., ManyaH., et al. (2001). Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell, 1, 717–724.
41.
YuM., HeY., WangK., et al. (2013). Adeno-associated viral-mediated LARGE gene therapy rescues the muscular dystrophic phenotype in mouse models of dystroglycanopathy. Hum. Gene Ther., 24, 317–330.
42.
ZhangP., and HuH. (2012). Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase. Glycobiology, 22, 235–247.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
